NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF OLAPARIB IN PATIENTS WITH TUMORS HARBORING DEFECTS IN DNA DAMAGE REPAIR GENES

Brief description of study

The primary purpose of the study is to determine the effectiveness and tolerability of the investigational drug olaparib for patients diagnosed with advanced solid tumors, non-Hodgkin lymphomas or histiocytic disorders. We want to understand how olaparib may affect the body or tumor and prevent the worsening of the symptoms. Olaparib is an investigation drug in this study because it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.


Clinical Study Identifier: s18-01968
ClinicalTrials.gov Identifier: NCT03233204
Principal Investigator: Mark E Weinblatt
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.